Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (INTEGRAL)

Investigator: Jenny Chang, MD

Study Coordinator: Kelsey Banaglorioso

Status: Open Not Enrolling Number: NCT04095689

Phone: 346.238.5740

Protocol Number: PRO00028602


The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative breast cancer (TNBC).
More to Explore